Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
Journal of Virology|July 1, 2011
Targeting OX40 promotes lung-resident memory CD8 T cell populations that protect against respiratory poxvirus infectionShahram Salek-Ardakani, Magdalini Moutaftsi, Alessandro Sette, et al.Journal of Immunology (Baltimore, Md. : 1950)|November 20, 2008
OX40 drives protective vaccinia virus-specific CD8 T cellsShahram Salek-Ardakani, Magdalini Moutaftsi, Shane Crotty, et al.European Journal of Immunology|February 19, 2009
Correlates of protection efficacy induced by vaccinia virus-specific CD8+ T-cell epitopes in the murine intranasal challenge modelMagdalini Moutaftsi, Shahram Salek-Ardakani, Michael Croft, et al.Nature Biotechnology|June 13, 2006
A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virusMagdalini Moutaftsi, Bjoern Peters, Valerie Pasquetto, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 21, 2008
Dissociation between epitope hierarchy and immunoprevalence in CD8 responses to vaccinia virus western reserveCarla Oseroff, Bjoern Peters, Valerie Pasquetto, et al.Vaccine|May 1, 2012
Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cellsLaura P Schneider, Antoinet J Schoonderwoerd, Magdalini Moutaftsi, et al.Vaccine|October 15, 2013
TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responsesChristopher B Fox, Magdalini Moutaftsi, Julie Vergara, et al.Journal of Pharmaceutical Sciences|January 28, 2014
Modulating potency: Physicochemical characteristics are a determining factor of TLR4-agonist nanosuspension activityQuinton M Dowling, Sandra J Sivananthan, Jeff A Guderian, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 2, 2013
Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cellsSusan L Baldwin, Lance K Ching, Samuel O Pine, et al.Plos One|July 26, 2012
Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140Mauricio A Arias, Griet A Van Roey, John S Tregoning, et al.Pageof 2